{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:06:04Z","timestamp":1790996764269,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.drudis.2019.02.006","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T19:19:28Z","timestamp":1550863168000},"page":"1427-1432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Emerging targets of inflammation and tear secretion in dry eye disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Maria","family":"Markoulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-0384","authenticated-orcid":false,"given":"Alex","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul. Surf."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1080\/02713683.2018.1433860","article-title":"The effect of optive and optive advanced artificial tears on the healthy tear film","volume":"43","author":"Markoulli","year":"2018","journal-title":"Curr. Eye Res."},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/02713683.2016.1233986","article-title":"Immediate effect of 3% diquafosol ophthalmic solution on tear MUC5AC concentration and corneal wetting ability in normal and experimental keratoconjunctivitis sicca rat models","volume":"42","author":"Choi","year":"2017","journal-title":"Curr. Eye Res."},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0030","first-page":"96","article-title":"Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model","volume":"42","author":"Fujihara","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.112.202473","article-title":"Nucleotides in the eye: focus on functional aspects and therapeutic perspectives","volume":"345","author":"Guzman-Aranguez","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-4835(03)00068-X","article-title":"Localization of ocular P2Y2 receptor gene expression by in situ hybridization","volume":"77","author":"Cowlen","year":"2003","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.02.006_bib0045","first-page":"929","article-title":"The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)-knockout mice","volume":"20","author":"Kojima","year":"2014","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2019.02.006_bib0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.exer.2015.10.013","article-title":"Diquafosol promotes corneal epithelial healing via intracellular calcium-mediated ERK activation","volume":"143","author":"Byun","year":"2016","journal-title":"Exp. Eye Res."},{"issue":"4","key":"10.1016\/j.drudis.2019.02.006_bib0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/10807680260218524","article-title":"INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model","volume":"18","author":"Fujihara","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.drudis.2019.02.006_bib0060","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bjophthalmol-2014-306084","article-title":"A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore","volume":"99","author":"Gong","year":"2015","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1089\/10807680151125519","article-title":"Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects","volume":"17","author":"Mundasad","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"Pt. B","key":"10.1016\/j.drudis.2019.02.006_bib0070","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/978-1-4615-0717-8_180","article-title":"Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease","volume":"506","author":"Yerxa","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.drudis.2019.02.006_bib0075","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","article-title":"A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients","volume":"96","author":"Takamura","year":"2012","journal-title":"Br. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2013.11.017","article-title":"Combination therapy with diquafosol tetrasodium and sodium hyaluronate in patients with dry eye after laser in situ keratomileusis","volume":"157","author":"Toda","year":"2014","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.02.006_bib0085","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/OPTH.S148167","article-title":"Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction","volume":"11","author":"Amano","year":"2017","journal-title":"Clin. Ophthalmol."},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0090","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10384-013-0251-y","article-title":"Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye","volume":"57","author":"Koh","year":"2013","journal-title":"Jpn. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.drudis.2019.02.006_bib0095","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","article-title":"Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye","volume":"23","author":"Tauber","year":"2004","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/eye.2016.54","article-title":"The increase of aqueous tear volume by diquafosol sodium in dry-eye patients with Sjogren\u2019s syndrome: a pilot study","volume":"30","author":"Yokoi","year":"2016","journal-title":"Eye (Lond.)"},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2013.09.009","article-title":"Facilitation of tear fluid secretion by 3% diquafosol ophthalmic solution in normal human eyes","volume":"157","author":"Yokoi","year":"2014","journal-title":"Am. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0110","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/bjophthalmol-2012-302668","article-title":"Topical diquafosol for patients with obstructive meibomian gland dysfunction","volume":"97","author":"Arita","year":"2013","journal-title":"Br. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.drudis.2019.02.006_bib0115","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","article-title":"Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial","volume":"119","author":"Matsumoto","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.drudis.2019.02.006_bib0120","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jtos.2017.03.005","article-title":"Increase in tear film lipid layer thickness after instillation of 3% diquafosol ophthalmic solution in healthy human eyes","volume":"15","author":"Fukuoka","year":"2017","journal-title":"Ocul. Surf."},{"issue":"8","key":"10.1016\/j.drudis.2019.02.006_bib0125","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/ICO.0000000000001241","article-title":"Effects of diquafosol ophthalmic solution on quality of life in dry eye assessed using the dry eye-related quality-of-life score questionnaire: effectiveness in patients while reading and using visual display terminals","volume":"36","author":"Utsunomiya","year":"2017","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0130","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10384-016-0430-8","article-title":"Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome","volume":"60","author":"Jin","year":"2016","journal-title":"Jpn. J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0135","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/jop.2012.0246","article-title":"Effects of diquafosol tetrasodium administration on visual function in short break-up time dry eye","volume":"29","author":"Kaido","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.drudis.2019.02.006_bib0140","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1111\/aos.12443","article-title":"Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye","volume":"92","author":"Koh","year":"2014","journal-title":"Acta Ophthalmol."},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0145","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/cxo.12521","article-title":"Effect of diquafosol three per cent ophthalmic solution on tear film and corneal aberrations after cataract surgery","volume":"100","author":"Lee","year":"2017","journal-title":"Clin. Exp. Optom."},{"issue":"9","key":"10.1016\/j.drudis.2019.02.006_bib0150","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1167\/iovs.10-6220","article-title":"Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated","volume":"52","author":"Samudre","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"25","key":"10.1016\/j.drudis.2019.02.006_bib0155","doi-asserted-by":"crossref","first-page":"18146","DOI":"10.1074\/jbc.M112.436584","article-title":"Lacritin rescues stressed epithelia via rapid forkhead box O3 (FOXO3)-associated autophagy that restores metabolism","volume":"288","author":"Wang","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.drudis.2019.02.006_bib0160","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1167\/iovs.14-13924","article-title":"Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease","volume":"55","author":"Vijmasi","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.drudis.2019.02.006_bib0165","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/ICO.0b013e3181a2ad81","article-title":"Mass spectrometry-based proteomic analyses in contact lens-related dry eye","volume":"28","author":"Nichols","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.drudis.2019.02.006_bib0170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.exer.2013.05.020","article-title":"Lacritin and the tear proteome as natural replacement therapy for dry eye","volume":"117","author":"Karnati","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.02.006_bib0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.exer.2015.08.015","article-title":"Lacritin and other autophagy associated proteins in ocular surface health","volume":"144","author":"Karnati","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.drudis.2019.02.006_bib0180","unstructured":"Odrich, M. (2017) NCT03226444: Lacripep\u2122 in Subjects With Dry Eye Associated With Primary Sj\u00f6gren\u2019s Syndrome. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03226444?view=record [Accessed 16 January 2019]"},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/02713683.2013.834939","article-title":"Regulation of human corneal epithelial mucins by rebamipide","volume":"39","author":"Itoh","year":"2014","journal-title":"Curr. Eye Res."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0190","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12325-017-0487-x","article-title":"A clinic-based survey of clinical characteristics and practice pattern of dry eye in Japan","volume":"34","author":"Kawashima","year":"2017","journal-title":"Adv. Ther."},{"issue":"7","key":"10.1016\/j.drudis.2019.02.006_bib0195","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s10620-008-0507-4","article-title":"Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test","volume":"54","author":"Iijima","year":"2009","journal-title":"Dig. Dis. Sci."},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0200","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.3892\/etm.2017.4390","article-title":"Effect of topical rebamipide on goblet cells in the lid wiper of human conjunctiva","volume":"13","author":"Kase","year":"2017","journal-title":"Exp. Ther. Med"},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0205","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1167\/iovs.17-23213","article-title":"The role of 2% rebamipide eye drops related to conjunctival differentiation in superoxide dismutase-1 (Sod1) knockout mice","volume":"59","author":"Kojima","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2013.11.010","article-title":"A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye","volume":"157","author":"Kinoshita","year":"2014","journal-title":"Am. J. Ophthalmol."},{"issue":"12","key":"10.1016\/j.drudis.2019.02.006_bib0215","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1167\/iovs.13-13128","article-title":"The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice","volume":"54","author":"Ohguchi","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.drudis.2019.02.006_bib0220","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1089\/jop.2012.0054","article-title":"Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells","volume":"29","author":"Ueta","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098390","article-title":"Anti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sjogren\u2019s syndrome","volume":"9","author":"Arakaki","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.drudis.2019.02.006_bib0230","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1167\/iovs.12-11294","article-title":"Protection of human corneal epithelial cells from TNF-alpha-induced disruption of barrier function by rebamipide","volume":"54","author":"Kimura","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1089\/jop.2011.0147","article-title":"Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cells density in normal rabbits","volume":"28","author":"Urashima","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2011.0142","article-title":"Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells","volume":"28","author":"Takeji","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0245","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1272\/jnms.82.229","article-title":"Improvements in signs and symptoms of dry eye after instillation of 2% rebamipide","volume":"82","author":"Igarashi","year":"2015","journal-title":"J. Nippon Med. Sch."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2019.02.006_bib0250","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/ICL.0000000000000438","article-title":"Efficacy of rebamipide instillation for contact lens discomfort with dry eye","volume":"44","author":"Igarashi","year":"2018","journal-title":"Eye Contact Lens"},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0255","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000369201","article-title":"Alkali burn treated with 2% rebamipide ophthalmic suspension: a case report","volume":"5","author":"Sasaki","year":"2014","journal-title":"Case Rep. Ophthalmol."},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0260","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2332\/allergolint.13-OA-0605","article-title":"Usefulness of a new therapy using rebamipide eyedrops in patients with VKC\/AKC refractory to conventional anti-allergic treatments","volume":"63","author":"Ueta","year":"2014","journal-title":"Allergol. Int."},{"issue":"4 Suppl. 1","key":"10.1016\/j.drudis.2019.02.006_bib0265","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/OPX.0000000000000523","article-title":"Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye","volume":"92","author":"Yamane","year":"2015","journal-title":"Optom. Vis. Sci."},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0270","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000445371","article-title":"Two patients with dry eye disease followed up using an expression assay of ocular surface mucin","volume":"7","author":"Machida","year":"2016","journal-title":"Case Rep. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.02.006_bib0275","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/2045-7022-4-40","article-title":"Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops","volume":"4","author":"Ueta","year":"2014","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.drudis.2019.02.006_bib0280","doi-asserted-by":"crossref","first-page":"10248","DOI":"10.1038\/srep10248","article-title":"JBP485 promotes tear and mucin secretion in ocular surface epithelia","volume":"5","author":"Nakamura","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0285","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0022-3565(24)39100-1","article-title":"Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats","volume":"294","author":"Liu","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20133","key":"10.1016\/j.drudis.2019.02.006_bib0290","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejphar.2008.04.066","article-title":"Protective effect of JBP485 on concanavalin A-induced hepatocyte toxicity in primary cultured rat hepatocytes","volume":"589","author":"Wu","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0295","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1211\/jpp.61.06.0009","article-title":"Protective effect of JBP485 on concanavalin A-induced liver injury in mice","volume":"61","author":"Yang","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0300","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.peptides.2011.01.031","article-title":"Effects of JBP485 on the expression and function of PEPT1 in indomethacin-induced intestinal injury in rats and damage in Caco-2 cells","volume":"32","author":"Wang","year":"2011","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/j.drudis.2019.02.006_bib0305","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s10620-006-9657-4","article-title":"Gastroprotective effects of DA-6034, a new flavonoid derivative, in various gastric mucosal damage models","volume":"52","author":"Choi","year":"2007","journal-title":"Dig. Dis. Sci."},{"issue":"4","key":"10.1016\/j.drudis.2019.02.006_bib0310","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF02979057","article-title":"Effect of DA-6034, a derivative of flavonoid, on experimental animal models of inflammatory bowel disease","volume":"22","author":"Kim","year":"1999","journal-title":"Arch. Pharm. Res."},{"issue":"20","key":"10.1016\/j.drudis.2019.02.006_bib0315","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","article-title":"The type 1 insulin-like growth factor receptor pathway","volume":"14","author":"Chitnis","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.drudis.2019.02.006_bib0320","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1200\/JCO.2007.15.9319","article-title":"Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma","volume":"26","author":"Lacy","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0091270011432934","article-title":"Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants","volume":"53","author":"Yin","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0330","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamaophthalmol.2013.8295","article-title":"The effects of insulin-like growth factor 1 and growth hormone on human meibomian gland epithelial cells","volume":"132","author":"Ding","year":"2014","journal-title":"JAMA Ophthalmol."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0335","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ajo.2004.10.022","article-title":"Dry eye in diabetic patients","volume":"139","author":"Kaiserman","year":"2005","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0340","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/aos.12063","article-title":"Meta-analysis and review on the changes of tear function and corneal sensitivity in diabetic patients","volume":"92","author":"Lv","year":"2014","journal-title":"Acta Ophthalmol."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0345","first-page":"235","article-title":"The dry eye and diabetes mellitus","volume":"91","author":"Seifart","year":"1994","journal-title":"Ophthalmologe"},{"issue":"9","key":"10.1016\/j.drudis.2019.02.006_bib0350","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1167\/iovs.14-14782","article-title":"The combined effect of azithromycin and insulin-like growth factor-1 on cultured human meibomian gland epithelial cells","volume":"55","author":"Liu","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.drudis.2019.02.006_bib0355","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2013.10.063","article-title":"Effect of insulin-like growth factor-1 on corneal surface ultrastructure and nerve regeneration of rabbit eyes after laser in situ keratomileusis","volume":"558","author":"Wang","year":"2014","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0360","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/bjo.2005.078865","article-title":"Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren\u2019s syndrome","volume":"90","author":"Aragona","year":"2006","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0365","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P 92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch. Intern. Med."},{"issue":"12","key":"10.1016\/j.drudis.2019.02.006_bib0370","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren\u2019s syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.drudis.2019.02.006_bib0375","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1517\/13543784.9.9.2007","article-title":"Sjogren's syndrome: current therapies remain inadequate for a common disease","volume":"9","author":"Fox","year":"2000","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"7","key":"10.1016\/j.drudis.2019.02.006_bib0380","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.ophtha.2010.12.016","article-title":"Treatment of Sjogren\u2019s syndrome-associated dry eye an evidence-based review","volume":"118","author":"Akpek","year":"2011","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0385","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/13543784.12.2.247","article-title":"Sjogren\u2019s syndrome: evolving therapies","volume":"12","author":"Fox","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"3\u20134","key":"10.1016\/j.drudis.2019.02.006_bib0390","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2739\/kurumemedj.56.39","article-title":"Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjogren\u2019s syndrome model mice","volume":"56","author":"Nishimura","year":"2009","journal-title":"Kurume Med. J."},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0395","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sjogren\u2019s syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0400","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","article-title":"A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren\u2019s syndrome patients with xerostomia and keratoconjunctivitis sicca","volume":"46","author":"Petrone","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0405","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international Dry Eye WorkShop (2007)","volume":"5","author":"Lemp","year":"2007","journal-title":"Ocul. Surf."},{"issue":"3","key":"10.1016\/j.drudis.2019.02.006_bib0410","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.survophthal.2009.02.002","article-title":"Topical ophthalmic cyclosporine: pharmacology and clinical uses","volume":"54","author":"Donnenfeld","year":"2009","journal-title":"Surv. Ophthalmol."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0415","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-016-0681-1","article-title":"Lifitegrast ophthalmic solution 5%: a review in dry eye disease","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0420","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","article-title":"Lifitegrast, a novel integrin antagonist for treatment of dry eye disease","volume":"14","author":"Perez","year":"2016","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.drudis.2019.02.006_bib0425","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/OPTH.S110557","article-title":"Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease","volume":"10","author":"Semba","year":"2016","journal-title":"Clin. Ophthalmol."},{"issue":"7","key":"10.1016\/j.drudis.2019.02.006_bib0430","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/jop.2018.0047","article-title":"Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast","volume":"34","author":"Guimaraes De Souza","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0435","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0440","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/jop.2009.0105","article-title":"Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults","volume":"27","author":"Semba","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.drudis.2019.02.006_bib0445","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.drudis.2019.02.006_bib0450","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.drudis.2019.02.006_bib0455","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.drudis.2019.02.006_bib0460","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: results of a phase iii, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.drudis.2019.02.006_bib0465","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical review: topical ophthalmic use of cyclosporin A","volume":"18","author":"Utine","year":"2010","journal-title":"Ocul. Immunol. Inflamm."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:42:31Z","timestamp":1761223351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618303957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1359644618303957"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.02.006","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging targets of inflammation and tear secretion in dry eye disease","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}